37 studies found for:    "Thyroid cancer anaplastic"
Show Display Options
Download search resultsDownload the search results for:
"Thyroid cancer anaplastic" (37 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Withdrawn Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Interventions: Drug: Fosbretabulin  + paclitaxel + carboplatin;   Drug: Placebo +  paclitaxel + carboplatin
2 Not yet recruiting A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Thyroid Cancer
Intervention: Drug: MLN0128
3 Completed Review of Multimodality Management of Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Intervention:
4 Recruiting A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Conditions: Solid Tumor;   Anaplastic Thyroid Cancer
Interventions: Drug: Crolibulin;   Drug: Cisplatin
5 Not yet recruiting National Anaplastic Thyroid Cancer Tissue Bank and Database (NATT)
Condition: Anaplastic Thyroid Cancer
Intervention: Other: Tissue, blood and clinical data collection
6 Terminated
Has Results
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer
Intervention: Drug: sorafenib tosylate
7 Not yet recruiting Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer
Interventions: Drug: efatutazone;   Drug: paclitaxel
8 Recruiting Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Interventions: Drug: paclitaxel;   Drug: pazopanib hydrochloride;   Other: placebo;   Radiation: intensity-modulated radiation therapy
9 Terminated
Has Results
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Interventions: Drug: CA4P;   Drug: paclitaxel;   Drug: carboplatin
10 Completed A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
Condition: Anaplastic Thyroid Cancer
Interventions: Drug: CS7017;   Drug: Paclitaxel
11 Active, not recruiting Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Conditions: Thyroid Neoplasms;   Carcinoma;   Thyroid Cancer;   Metastatic Cancer
Intervention: Drug: Bevacizumab
12 Completed Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Condition: Head and Neck Cancer
Intervention: Drug: fosbretabulin disodium
13 Terminated
Has Results
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
Condition: Thyroid Cancer
Intervention: Drug: Imatinib
14 Terminated Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fosbretabulin disodium;   Radiation: radiation therapy
15 Recruiting Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Nonmedullary Carcinoma
Interventions: Drug: lapatinib ditosylate;   Drug: dabrafenib;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
17 Completed Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Metastatic Parathyroid Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Parathyroid Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Non-small Cell Lung Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Thryoid Gland Nonmedullary Carcinoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Intervention: Drug: gefitinib
18 Terminated Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
19 Active, not recruiting Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
20 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pineal Gland Astrocytoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Anaplastic Thyroid Cancer;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Cancer;   Extra-adrenal Paraganglioma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrinoma;   Glucagonoma;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Insular Thyroid Cancer;   Insulinoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Pancreatic Polypeptide Tumor;   Peripheral T-cell Lymphoma;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Tumor;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Islet Cell Carcinoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Small Intestine Lymphoma;   Somatostatinoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adult Soft Tissue Sarcoma;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Follicular Thyroid Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Rectal Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Colon Cancer;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Colon Cancer;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Rectal Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: romidepsin;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
Indicates status has not been verified in more than two years